The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Medvedev V.E.

Peoples’ Friendship University of Russia

Kardashian R.A.

Peoples’ Friendship University of Russia

Frolova V.I.

Peoples’ Friendship University of Russia

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders

Authors:

Medvedev V.E., Kardashian R.A., Frolova V.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6): 101‑109

DOI: 10.17116/jnevro2024124061101

Views: 1667

Downloaded: 7

Buy for 300₽
Contact the author
Table of contents

FLUVOXAMINE IN THE TREATMENT OF ANXIETY-DEPRESSIVE SPECTRUM DISORDERS
FLUVOXAMINE IN THE TREATMENT OF ANXIETY-DEPRESSIVE SPECTRUM DISORDERS

To cite this article:

Medvedev VE, Kardashian RA, Frolova VI. Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):101‑109. (In Russ.)
https://doi.org/10.17116/jnevro2024124061101

 
 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Pathogenetic basis of modern approaches to the therapy of sleep diso­rders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74
Features of the clinical picture of affe­ctive diso­rders in women during the meno­pausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79
Resu­lts of a pilot study of the stru­cture and evaluation of the therapy for chro­nic sleep diso­rders in como­rbid patients with chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):118-126
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Sleep diso­rders and onco­logical diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131
Features of cognitive impairment in bipo­lar affe­ctive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):15-19
Reco­gnan (citicoline) in the correction of asthenic and anxiety-depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47
Anti­depressants in psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):126-132

The RSCI and PubMed search databases have requested publications over the past 40 years on the search queries «fluvoxamine», «anxiety-depressive disorders», «anxiety», «depression», «comorbidity», devoted to the effectiveness of fluvoxamine in various variants of disorders of the anxiety-depressive spectrum, anxiety depressions. The data of the above studies indicate that fluvoxamine (Zovart San) in doses of 50-300 mg / day is a highly effective remedy for the treatment of not only anxiety depressions and genesis (psychogenic, organic, mixed, autochthonous-endogenous) and severity (up to psychotic), but also a wider range of anxiety-depressive disorders, including adaptation disorders, obsessive-compulsive disorder, somatized, dysmorphic, insomniac symptom complexes and eating disorders. A wide range of clinical effects of fluvoxamine is due to its main and additional mechanisms of action: blockade of serotonin reuptake, σ1-agonist activity and the effect on the metabolism of melatonin and neurosteroids catabolism.

Keywords:

fluvoxamine
anxiety and depressive disorders
anxiety disorders
depression
comorbidity
Zovart San

Authors:

Medvedev V.E.

Peoples’ Friendship University of Russia

Kardashian R.A.

Peoples’ Friendship University of Russia

Frolova V.I.

Peoples’ Friendship University of Russia

Received:

22.05.2024

Accepted:

19.06.2024

List of references:

  1. Ionescu DF, Niciu MJ, Henter ID, et al. Defining anxious depression: a review of the literature. CNS Spectr. 2013;18(5):252-260.  https://doi.org/10.1017/S1092852913000114
  2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.  https://doi.org/10.1001/archpsyc.1994.03950010008002
  3. Kennedy SH, Lam RW, McIntyre RS, et al. CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540-560.  https://doi.org/10.1177/0706743716659417
  4. Medvedev VE. Efficacy and tolerability of contemporary antidepressants: results of network meta-analyses and Russian experience. S.S. Korsakov Journal of Neurology and Psychiatry. 018;118(11):109-117. (In Russ.). https://doi.org/10.17116/jnevro2018118111109
  5. Mosolov SN, Parfenov VA, Amelin AV, et al. Depressive disorders and their pharmacotherapy in routine clinical practice. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(5):54-64. (In Russ.). https://doi.org/10.14412/2074-2711-2023-5-54-64
  6. Lin CH, Wang FC, Lin SC, et al. A comparison of inpatients with anxious depression to those with nonanxious depression. Psychiatry Res. 2014;220(3):855-860.  https://doi.org/10.1016/j.psychres.2014.08.048
  7. González HM, Tarraf W, Whitfield K, et al. Vascular depression prevalence and epidemiology in the United States. J Psychiatr Res. 2012;46(4):456-461.  https://doi.org/10.1016/j.jpsychires.2012.01.011
  8. Bobrov AE, Krasnoslobodtseva LA, Mutnykh EM. Procognitive effects of fluvoxamine: preliminary data. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6):43-49. (In Russ.). https://doi.org/10.17116/jnevro20181186143
  9. Flint AJ, Rifat SL. Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry. 1997;5(2):107-115. 
  10. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 201;11(2 Pt 2):300-307.  https://doi.org/10.3109/15622970701432528
  11. Medvedev VE. Treatment of mental disorders of generative cycle in women. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):84-90. (In Russ.). https://doi.org/10.14412/2074-2711-2022-2-84-90
  12. Medvedev VE, Ter-Israelian AYu, Frolova VI, et al. Optimization of therapy of mental disorders with a multisyndromic clinical picture. Psychiatry and psychopharmacotherapy named after P.B. Gannushkin. 2020;1:23-27. (In Russ.).
  13. Sierra M, Medford N, Wyatt G, et al. Depersonalization disorder and anxiety: a special relationship? Psychiatry Res. 2012;197(1-2):123-127.  https://doi.org/10.1016/j.psychres.2011.12.017
  14. Kotova OV, Frolova VI, Medvedev VE. Efficacy and tolerability of fluvoxamine (Rokona) in the treatment of depression in patients with cardiovascular pathology. Psychiatry and psychopharmacotherapy. 2022;2:34-39. (In Russ.).
  15. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351.  https://doi.org/10.1176/appi.ajp.2007.06111868
  16. Panzer MJ. Are SSRIs really more effective for anxious depression? Ann Clin Psychiatry. 2005;17(1):23-29.  https://doi.org/10.1080/10401230590905317
  17. Stahl SM, Lee-Zimmerman C, Cartwright S, et al. Serotonergic drugs for depression and beyond. Curr Drug Targes. 2013;14(5):578-585.  https://doi.org/10.2174/1389450111314050007
  18. Medvedev VE. Sigma receptors: the role in the treatment of affective disorders. Neurology, neuropsychiatry and psychosomatics. 2012;2:105-107. (In Russ.).
  19. Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010;3:CD006114.
  20. Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005;1(4):289-299. 
  21. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol. 1987;7(Suppl. 6):36S-43S. 
  22. Bekker RA, Bykov YuV. Fluvoxamine: a broad spectrum antidepressant with several distinctive niches for its clinical use (a literature review). Psychiatry and Psychopharmacotherapy. 2019;21(1):11-26. (In Russ.).
  23. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29(Suppl. 1):1-9. 
  24. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006;60(4):482-491. 
  25. Romasenko LV, Shanaeva IA. Lechenie rasstroistv sna pri depressii u patsientov s somaticheskimi zabolevaniiami. Handbook for Practitioners Doctors. 2008;13:58-62. (In Russ).
  26. Tereshchenko ON, Cost NV, Medvedev VE. Modern trends in pathogenetic therapy of anxiety. Literature review. Part 2. Psychiatry. 2018;2:106-115. (In Russ.).
  27. Mazo GE, Neznanov NG. Terapevticheski rezistentnye depressii. SPb., 2012. (In Russ).
  28. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15-29. 
  29. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol Clin Exp. 2010;25:193-200. 
  30. Ivanov MV, Sorokina AV. Vliianie farmakoterapii antidepressantami na kognitivnye funktsii pri depressivnykh rasstroistvakh: vozmozhnosti primeneniia fluvoksamina. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. 2014;3:22-127. (In Russ).
  31. Diukova GM. Rasstroistva adaptatsii v meditsinskoi praktike: diagnostika i terapiia. Effektivnaia farmakoterapiia. 2010;16:6-11. (In Russ).
  32. Dolzhenko MM. Depressivnye i trevozhnye rasstroistva v kardiologii: vozmozhnosti kombinirovannoi terapii antidepressantom i antigipoksantom. Mezhdunar. nevrol. zhurn. 2013;5(59):152-160. (In Russ).
  33. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 2014;727:167-173. 
  34. Syunyakov TS. Effects of fluvoxamine on the melatonin levels: literature overview and possible clinical implication. Psychiatry and Psychopharmacotherapy. 2014;16(1):33-38. (In Russ).
  35. Khannanova AN, Bykov YuV, Bekker RA. Prospects for the use of melatonin in the treatment of various mental disorders (Literature review). In the World of Scientific Discoveries. 2017; 1 (9): 131-149. (In Russ).
  36. Hasebe S, Ago Y, Watabe Y, et al. Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice. Br J Pharmacol. 2017;174(4):314-327.  https://doi.org/10.1111/bph.13692
  37. Chen T, Tanaka M, Wang Y, et al. Neurosteroid dehydroepiandrosterone enhances activity and trafficking of astrocytic GLT-1 via s1 receptor-mediated PKC activation in the hippocampal dentate gyrus of rats. Glia. 2017;65(9):1491-1503. https://doi.org/10.1002/glia.23175
  38. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand. 1990;81(2):185-189.  https://doi.org/10.1111/j.1600-0447.1990.tb06476.x
  39. Houck C. An open-label pilot study of fluvoxamine for mixed anxiety-depression. Psychopharmacol Bull. 1998;34 (2):225-227. 
  40. Lopukhov IG, Andrusenko MP, Vladimirova TV, et al. Clinical evaluation of fluoxetine antidepressant activity. S.S. Korsakov Journal of Neurology and Psychiatry. 1994,6:76-81. (In Russ).
  41. Panteleeva GP, Abramova LI, Korenev AN. Selective serotonin reuptake inhibitors in the therapy of various types of endogenous depressions. S.S. Korsakov Journal of Neurology and Psychiatry. 2000;100 (3):36-41. (In Russ).
  42. Antipova OS, Krasnov VN, Trofimova OS. The changes in the autonomic regulation in depressive disorders of moderate severity. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(11 Pt 2):65-73. (In Russ).
  43. Gurovich IYa, Shmukler AB, Salnikova LI, et al. The use of fevarin for long-term therapy in community psychiatric practice. Criteria and indicators of its assessment. Social and clinical psychiatry. 2003;13(4):42-46. (In Russ).
  44. Medvedev VE. Dysmorphic disorder: heterogeneousrisk factors and clinical-dynamic characteristics. Psychiatry and psychopharmacotherapy. 2021;2:29-36. (In Russ).
  45. Medvedev VE, Frolova VI, Martynov SE, et al. Dysmorphic disorder in the structure of mental disorders of plastic surgeon and cosmetologist patients. Mental health. 2017;2:48-55. (In Russ).
  46. Medvedev VE, Barseghyan TV, Drobyshev AV. Therapy of depressive and anxiety disorders in patients seeking surgical correction of appearance. Mental health. 2012;5(72):40-45. (In Russ).
  47. Phillips KA, Siniscalchi JM, McElroy SL. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Q. 2004;75(4):309-320.  https://doi.org/10.1023/b:psaq.0000043507.03596.0d
  48. Medvedev VE. Diagnosis and Therapy of Psychosomatic Disorders in Reproductive Cycle of Women in General Medical Practice (Review). The Russian Archives of Internal Medicine. 2022;12(4):276-284.  https://doi.org/10.20514/2226-6704-2022-12-4-276-284
  49. Medvedev VE, Frolova VI, Kotova OV. Therapy of cardioneurosis with modern antidepressants in general medical care network. Medical alphabet. 2021;(25):26-32. (In Russ.). https://doi.org/10.33667/2078-5631-2021-25-26-32
  50. Smulevich AB, Medvedev VE, Zheleznova MV, et al. Therapy of mental disorders in cardiology. Methodological recommendations for the use of the drug «FEVARIN». M.; 2012:28 p. (In Russ).
  51. Walczak DD, Apter JT, Halikas JA, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry. 1996;8(3):139-151.  https://doi.org/10.3109/10401239609147751
  52. Bekker RA, Bykov YuV. Anxious and dyssomnic depressive disorders: distinctive clinical features, diagnosis, therapy and Rocona® (fluvoxamine) efficacy. Psychiatry and Psychopharmacotherapy. 2019;21(3):17-23. (In Russ).
  53. Medvedev VE, Titova NV, Milyukhina IV, et al. Slow-wave sleep and the possibilities of modern insomnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8):49-55. (In Russ.). https://doi.org/10.17116/jnevro202312308149
  54. Kotova OV, Belyaev AA, Medvedev VE, et al. Hypersomnia in mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5 vyp 2):63-68. (In Russ.). https://doi.org/10.17116/jnevro202312305263
  55. Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the Biotransformation of Melatonin. J Clin Psychopharmacol. 2001;21:167-174. 
  56. Levin IaI, Koval’chuk MV. Depressiia i narusheniia sna. Effektivnaia farmakoterapiia. 2010;18:18-24. (In Russ).
  57. Dalery J, Honig A. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum Psychopharmacol. 2003;18:379-384. 
  58. Andriushchenko AV, Beskova DA. Terapevticheskie aspekty primeneniia fevarina (fluvoksamina maleata) po rezul’tatam naturalisticheskoi programmy Modus. Psychiatry and Psychopharmacotherapy. 2008;10(3):29-34. (In Russ).
  59. Kinkul’kina MA. Lechenie tiazhelykh endogennykh depressii fevarinom (fluvoksamin). Psychiatry and Psychopharmacotherapy. 2007;9(4):39-44. (In Russ).
  60. Smulevich AB, Ilyina NA, Chitlova VV. Fluvoxamine in Treatment of Depression In Russian Patients: An Open-Label Uncontrolled and Randomized Multicenter Observational Study. Psychiatry and Psychopharmacotherapy. 2016;18(1):4-10. (In Russ).
  61. Keltner NL, McAfee KM, Taylor CL. Mechanism and treatment of SSRis-induced sexual dysfunction. Perspect Psychiatr Care. 2002;38:111-116. 
  62. Silvestri R, Pace-Schott E, Gersh T, et al. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal. J Clin Psychiatry. 2001;62:642-652. 
  63. Gorenkov RV, Dvorina OG, Pozdnyakov YuM, et al. Evaluation of the effectiveness of the antidepressant fluvoxamine and its effect on the course of various forms of atrial fibrillation. Cardiovascular therapy and prevention. 2010;9(7):49-55. (In Russ).
  64. Shiriaev OIu, Budnevskii AV, Iankovskaia VL. Psikhosomaticheskie aspekty terapii khronicheskoi serdechnoi nedostatochnosti u bol’nykh s trevozhno-depressivnymi rasstroistvami. Prikladnye informatsionnye aspekty meditsiny. 2014;1(17):214-220. (In Russ).
  65. Gothelf D, Rubinstein M, Shemesh E, et al. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer. J Am Acad Child Adolesc Psychiatry. 2005;44(12):1258-1262. https://doi.org/10.1097/01.chi.0000181042.29208.eb
  66. Samushiia MA. Fevarin (Fluvoksamin) v terapii trevozhno-depressivnykh nozogennykh reaktsii u patsientov s onkologicheskimi zabolevaniiami. Mental Disorders in General Medicine. 2008;1:33-37. (In Russ).
  67. Fedotova AV. Trevozhno-depressivnye rasstroistva v obshcheklinicheskoi praktike. Ratsional’naia farmakoterapiia v kardiologii. 2008;3(4):83-90. (In Russ).
  68. Bryukhanov AV. The effectiveness of fevarin (fluvoxamine) in the treatment of autonomic disorders, comorbid neurotic conditions. International Neurological Journal. 2008;1:14-19. (In Russ).
  69. Gatti F, Bellini L, Gasperini M, et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry. 1996;153(3):414-416. 
  70. Shirayama Y, Hashimoto K. A case of psychotic depression treated with fluvoxamine monotherapy. Clin Psychopharmacol Neurosci. 2010;8:53-54. 
  71. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. Ann Gen Psychiatry. 2009;8:26. 
  72. Zanardi R, Franchini L, Gasperini M, et al. Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol. 1997;12:195-197. 
  73. Zanardi R, Franchini L, Serretti A, et al. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry. 2000;61:26-29. 
  74. Van den Broek WW, Birkenhäger TK, Mulder PG, et al. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology (Berl). 2004;175(4):481-486. 
  75. Kishimoto A, Todani A, Miura J, et al. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report. Ann Gen Psychiatry. 2010;9:23. 
  76. Svestka J, Cesková E, Rysánek R, et al. [The status of fluvoxamine among the antidepressive agents]. [Article in Czech]. Cesk Psychiatr. 1992;88(5):209-219. 
  77. Medvedev VE, Kardashyan RA, Frolova VI, et al. Investigation of the efficiency of various antidepressant replacement regimens in the development of SSRI-induced apathy syndrome. Nevrologiya, neiropsikhiatriya, psikhosomatika. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):48-56. (In Russ).
  78. Morozov PV. Fluvoxamine is included in the Russian temporary recommendations for the treatment of COVID-19 and other similar protocols in a number of countries (review of the latest data). Psychiatry and psychopharmacotherapy. 2022;1:49-50. (In Russ).
  79. Kotova OV, Medvedev VE, Poluektov MG, et al. Sleep disorders in post-COVID syndrome — a problem of psychiatry or neurology? S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5 vyp 2):23-28. (In Russ.). https://doi.org/10.17116/jnevro202212205223
  80. Kotova OV, Artemenko AR, Belyaev AA, et al. Respiratory panic attacks and COVID-19. Practical medicine. 2021;19(1):29-33.  https://doi.org/10.32000/2072-1757-2021-1-29-33
  81. Medvedev VE. Anxiety and depression in COVID-19: treatment options. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):111-116.  https://doi.org/10.14412/2074-2711-2021-2-111-116
  82. Medvedev VE, Dogotar OA. COVID-19 and mental health: challenges and first conclusions. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):4-10. (In Russ.). https://doi.org/10.14412/2074-2711-2020-6-4-10
  83. Petrova NN, Markin AV. Choosing an antidepressant during the COVID-19 pandemic. Psychiatry and Psychopharmacotherapy. 2021;23(6):16-22. (In Russ).
  84. Petrova NN, Markin AV, Morozov PV. Postcovid syndrome: prevalence and methods of treatment of neuropsychiatric complications. Focus on fluvoxamine. Psychiatry and psychopharmacotherapy. 2021;4:42-48. (In Russ).
  85. Morozov PV, Bykov YuV, Bekker RA. Long COVID and its treatment: new role of Sigma-1 receptors and fluvoxamine (A Literature Review and a Clinical Case). Psychiatry and psychopharmacotherapy. 2022;3:33-47. (In Russ).
  86. Dubnitskaia EB. Opyt primeneniia fluvoksamina (fevarina) pri psikhogennykh depressiiakh. Psychiatry and Psychopharmacotherapy. 2005;7(2):77-8. (In Russ).
  87. Sonawalla SB, Spillmann MK, Kolsky AR, et al. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry. 1999;60(9):580-583. 
  88. Medvedev VE. Fluvoxamine (Fevarin) in the treatment of obsessive-compulsive spectrum disorders. Journal of Psychiatry and Psychopharmacotherapy. 2015;1:44-49. (In Russ).
  89. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1. 
  90. Heidari M, Zarei M, Hosseini SM, et al. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2014;29(6):344-350. 
  91. Goryunov AV, Golubeva NI, Shushpanova OV. Experience of clinical use of fluvoxamine for the treatment of comorbid depression in childhood and adolescence. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11-2):14-21. (In Russ.). https://doi.org/10.17116/jnevro202312311214
  92. Westenberg H.M., Sandoz C. Tolerability and safety of fluvoxamine and other antidepressants. J Clin Pract. 2006;4:482-491. 
  93. Voloshin VM, Shilova AM. Fevarin in the treatment of obsessive-compulsive disorders in child and adolescent psychiatric practice. Pharmateca. 2006;7:109-113. (In Russ.).
  94. Fineberg N. Evidence-Based Pharmacotherapy for Obsessive-Compulsive Disorder. Advances in Psychiatric Treatment. 1999;5(5):357-365. 
  95. Koljuckaja EV. Fluvoxamine (Fevarin) in the treatment of obsessive-compulsive disorders. Farmateka. 2006;2:30-39. (In Russ.).
  96. Gardiner HM, Freeman CP, Jesinger DK, et al. Fluvoxamine: an open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing. Int J Obes Relat Metab Disord. 1993;17(5):301-305. 
  97. Medvedev VE, Frolova VI, Gushanskaya EV, et al. Depressions with eating disorders: clinical manifestations and therapy. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):49-56. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-49-56
  98. Dewulf L, Hendrickx B, Lesaffre E. Epidemiological data of patients treated with fluvoxamine: results from a 12 week non-comparative multicentre study. Int Clin Psychopharmacol. 1995;9(Suppl. 4):67-72. 

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.